Zogenix, Inc: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

Total revenue of $26.6 million in the fourth quarter and $81.7 million for the full yearFINTEPLA® net product sales of $23.5 million in the fourth quarter and $74.7 million for the full year Announced

Related Keywords

Germany ,Japan ,United States ,France ,Japanese ,American ,Porter Novelli ,Trish Mccall ,Tevard Biosciences ,Stephenj Farr ,Brian Ritchie ,Us Securities Exchange Commission ,Nippon Shinyaku Co Ltd ,Lifesci Advisors ,Zogenix Access Program ,Drug Application To Japan Ministry Of Health ,Drug Administration ,Zogenix Inc ,American Epilepsy Society Annual Meeting ,Exchange Commission ,Japanese Ministry Of Health ,European Medicines Agency ,Zinc Merger Sub Inc ,Priority Review ,Supplemental New Drug Application ,Lennox Gastaut Syndrome ,New Drug Application ,Access Program ,Japanese Ministry ,American Epilepsy Society Annual ,Fourth Quarter ,Results Compared ,Year Ended ,Investor Relations ,Zinc Merger Sub ,Recommendation Statement ,Merger Sub ,Private Securities Litigation Reform Act ,Zogenix ,Rovides ,Corporate ,Update ,Reports ,Fourth ,Quarter ,Bull ,Ear ,021 ,Financial ,Results ,